Circulating Serum Myonectin Levels in Obesity and Type 2 Diabetes Mellitus

Abstract

Objective Myonectin is one of the myokines and has gained interest as a potential new strategy to combat obesity and its associated disorders, such as type 2 diabetes mellitus (T2DM).The objective of this study was to investigate circulating serum myonectin levels in nondiabetes and T2DM and elucidate possible relationships between serum myonectin levels and metabolic parameters in patients with T2DM.

Design A total of 362 Chinese patients with T2DM and 100 age- and sex-matched healthy controls were recruited in this study. Clinical characteristics, blood biochemistry, and circulating myonectin levels were measured by enzyme-linked immunosorbent assay.

Results Circulating myonectin levels were significantly decreased in T2DM compared with controls. Obese nondiabetic controls had significantly lower serum myonectin levels compared with lean nondiabetic controls. In diabetic patients, serum myonectin concentrations were significantly negatively correlated with body mass index (BMI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), hemoglobin A1c (HbA1c), fasting insulin (Fins), the homeostatic model assessment of insulin resistance (HOMA-IR), visceral fat area, and subcutaneous fat area. After adjusting for covariates, multivariate stepwise regression analysis demonstrated that BMI, LDL-C, TG, HOMA-IR, and visceral fat were the main independent predictors of low serum myonectin concentrations.

Conclusions Circulating myonectin levels were decreased in T2DM patients and in obese subjects. Moreover, serum myonectin levels were correlated with metabolic markers of T2DM. These data suggest that myonectin may be a useful marker in predicting the development of obesity and T2DM.

Key words

Type 2 diabetes mellitus - serum myonectin - myokine

Publication History

Received: 16 October 2018
Received: 11 April 2019

Accepted: 17 April 2019

Article published online:
24 July 2019

• References

• 1 Febbraio MA, Pedersen BK. Contraction-induced myokine production and release: Is skeletal muscle an endocrine organ?. Exerc Sport Sci Rev 2005; 33: 114-119
• 2 Raschke S, Eckardt K. Holven KB et al. Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS One 2013; 8: e62008
• 3 Hartwig S, Raschke S, Knebel B. et al. Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta 2014; 1844: 1011-1017
• 4 Norheim F, Raastad T, Thiede B. et al. Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training. Am J Physiol Endocrinol Metab 2011; 301: E1013-E1021
• 5 Kishore U, Reid KBM. C1q: Structure, function, and receptors. Immunopharmacology 2000; 49: 159-170
• 6 Seldin MM, Peterson JM, Byerly MS. et al. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem 2012; 287: 1968-11980
• 7 Yang M, Wei D, Mo C. et al. Saturated fatty acid palmitateinduced insulin resistance is accompanied with myotube loss and the impaired expression of health benefit myokine genes in C2C12 myotubes. Lipids Health Dis 2013; 12: 104
• 8 Peterson JM, Mart R, Bond CE. Effect of obesity and exercise on the expression of the novel myokines, Myonectin and Fibronectin type III domain containing 5. PeerJ 2014; 30: e605
• 9 Lim S, Choi SH, Koo BK. et al. Effects of aerobic exercise training on C1q tumor necrosis factor alpha-related protein isoform 5 (myonectin): Association with insulin resistance and mitochondrial DNA density in women. J Clin Endocrinol Metab 2012; 97: E88-E93
• 10 Pedersen BK, Febbraio MA. Muscles, exercise and obesity: Skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8: 457-465
• 11 Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J Pharmacol Sci 2014; 25: 125-131
• 12 Giudice J, Taylor JM. Muscle as a paracrine and endocrine organ. Curr Opin Pharmacol 2017; 4: 49-55
• 13 Lee P, Linderman JD, Smith S. et al Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab 2014; 19: 302-309
• 14 Seldin MM, Wong GW. Regulation of tissue crosstalk by skeletal muscle-derived myonectin and other myokines. Adipocyte 2012; 1: 200-202
• 15 Park SY, Choi JH, Ryu HS. et al. C1q tumor necrosis factor alpha-related protein isoform 5 is increased in mitochondrial DNA-depleted myocytes and activates AMP-activated protein kinase. J Biol Chem 2009; 41: 7780-27789
• 16 Seldin MM, Lei X, Tan SY. et al Skeletal muscle-derived myonectin activates the mammalian target of rapamycin (mTOR) pathway to suppress autophagy in liver. J Biol Chem 2013; 50: 36073-36082
• 17 Kim KH, Jeong YT. Oh. et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 2013; 19: 83-92
• 18 Armani A, Cinti F, Marzolla V. et al. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014; 28: 3745-3757
• 19 Toloza FJK, Mantilla-Rivas JO, Pérez-Matos MC. et al., Plasma levels of myonectin but not myostatin or fibroblast-derived growth factor 21 are associated with insulin resistance in adult humans without diabetes mellitus. Front Endocrinol (Lausanne) 2018; 9: 5